Milad Alucozai

Dr. Milad Alucozai specializes in translating exceptional science and technology into scalable commercial ventures. As an Afghan-American neuroscientist, entrepreneur, and global investor, he leverages his expertise in bioengineering, computational biology, and machine learning to identify promising innovations and develop strategies for their successful market entry and growth. His focus is on accelerating the journey of groundbreaking discoveries from the lab to market, particularly within the life sciences sector and other computationally-driven fields.

Dr. Alucozai is a co-founder of Revalia Bio, which focuses on building a human-centric infrastructure for drug discovery and development. By utilizing non-transplantable human organs donated for research, Revalia provides the scientific community unparalleled insights into patient biology, ultimately aiding in the development of better treatments and cures. In 2024, in partnership with The Wyss Institute at Harvard University, Dr. Alucozai launched the "Code to Cure" series, which explores the convergence of artificial intelligence (AI), biology, and healthcare, highlighting the technologies and innovations shaping the future of human and planetary health. He actively mentors entrepreneurs across North America and Europe through channels like the Creative Destruction Lab. Additionally, he collaborates closely with various health systems and pharmaceutical companies, advising them on innovation adoption and venture strategy.

Previously, as Head of Bio and Deep Tech at BoxOne Ventures, he led 70 early-stage investments, establishing the firm as a leading player in North America’s venture capital landscape. He also served as a Venture Partner at Entrepreneur First, a globally recognized talent investor backed by notable figures like Patrick and John Collison of Stripe and Reid Hoffman of LinkedIn, with a portfolio exceeding $10 billion in value. Across his operating and investing career, he has been instrumental in helping founders secure hundreds of millions in capital and has supported over $1 billion in startup-pharma partnerships. Often serving as the first investor, he guides companies from concept to successful exit.

Dr. Alucozai holds the position of Senior Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

‍

‍